Drug Search Results

Duligotuzumab

Alternative Names: duligotuzumab
Latest Update: 2022-09-15
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: ERBB3 Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Duligotuzumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Head and Neck Cancer|Squamous Cell Carcinoma|Sarcoma

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
R/M SCCHN	P1	Completed	Head and Neck Cancer\|Squamous Cell Carcinoma	2017-06-22
GO29030	P1	Completed	Sarcoma	2016-01-01

Recent News Events

Date	Type	Title
09/15/2022	PubMed	Comparison of Second-Line Treatments for Patients with Platinum-Resistant Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Systematic Review and Bayesian Network Meta-Analysis.
05/12/2021	PubMed	Enhanced Antitumor Effect of Trastuzumab and Duligotuzumab or Ipatasertib Combination in HER-2 Positive Gastric Cancer Cells.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions